Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
1(10%)
Results Posted
44%(4 trials)

Phase Distribution

Ph phase_3
1
10%
Ph phase_4
2
20%
Ph not_applicable
2
20%
Ph phase_2
4
40%

Phase Distribution

0

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
4(44.4%)
Phase 3Large-scale testing
1(11.1%)
Phase 4Post-market surveillance
2(22.2%)
N/ANon-phased studies
2(22.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(9)

Detailed Status

Completed9
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 24 (44.4%)
Phase 31 (11.1%)
Phase 42 (22.2%)
N/A2 (22.2%)

Trials by Status

recruiting110%
completed990%

Recent Activity

1 active trials
Showing 5 of 10
recruiting

Host Response to Infection and Treatment in Filarial Diseases

NCT00001230
completedphase_3

Moxidectin for LF, Cote d'Ivoire (DOLF)

NCT04410406
completednot_applicable

Lymphatic Filariasis (LF) in Ivory Coast

NCT02974049
completedphase_2

Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis

NCT01111305
completedphase_2

PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )

NCT03664063
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00001230

Host Response to Infection and Treatment in Filarial Diseases

Recruiting
NCT04410406Phase 3

Moxidectin for LF, Cote d'Ivoire (DOLF)

Completed
NCT02974049Not Applicable

Lymphatic Filariasis (LF) in Ivory Coast

Completed
NCT01111305Phase 2

Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis

Completed
NCT03664063Phase 2

PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )

Completed
NCT01975441Phase 2

Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa

Completed
NCT01593722Phase 4

Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis

Completed
NCT00511004Phase 2

Effect of Albendazole Dose on Treatment of Lymphatic Filariasis

Completed
NCT02005653Phase 4

Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection

Completed
NCT00295698Not Applicable

Interaction Between HIV and Lymphatic Filariasis

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10